Lungpacer presents preclinical lung and brain data at 2023 American Thoracic Society (ATS) conference in Washington, DC.
- May 19, 2023
© 2024 Lungpacer Medical Inc. ®
The AeroPace System is approved by the United States Food and Drug Administration to improve weaning success in adult patients on MV at least 96 hours and who have not weaned. The AeroPace System is not approved in any other country.
CAUTION: The AeroNova System is limited by Federal law (United States) to investigational use. Used exclusively for clinical investigations.
Lungpacer® Medical, AeroPace® System and AeroNova® System are registered trademarks of Lungpacer Medical.
